JB/CALL/MODERNA/150/0.0166/20.09.24 | Market Closed - Swiss Exchange 08:50:00 26/06/2024 pm IST | ||
| 0.12 CHF | -20.00% |
|
| Current month | -55.56% | ||
| 1 month | -74.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 0.12 | -20.00% |
| 21/24/21 | 0.15 | -6.25% |
| 20/24/20 | 0.16 | +23.08% |
| 19/24/19 | 0.13 | -13.33% |
| 18/24/18 | 0.15 | -11.76% |
Delayed Quote Swiss Exchange
Last update June 26, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRZZJB | |
| ISIN | CH1263879806 |
| Date issued | 22/05/2023 |
| Strike | 150 $ |
| Maturity | 20/09/2024 (86 Days) |
| Parity | 60 : 1 |
| Emission price | 0.38 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.47 CHF |
|---|---|
| Lowest since issue | 0.04 CHF |
| Spread | 0.01 CHF |
| Spread % | 8.33% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.4
USD
Average target price
145.9
USD
Spread / Average Target
+19.11%
- Stock Market
- Warrants
- MRZZJB Warrant
